CBIZ Report Highlights Rising Costs: Surge in Inpatient and Outpatient Expenses, Popular GLP-1 Drugs like Ozempic Drive Pharmacy Spend Increase
New CBIZ State of Healthcare Report Reveals Cost Increases, Significant Impact of GLP-1 Drugs on Pharmacy Spend, and Regulatory Changes Expanding Employee Protections and Accessibility
Now, more than ever, employers face increased pressure to balance affordability with employee wellbeing as healthcare costs continue to rise. The State of Healthcare Report draws on CBIZ’s proprietary data from more than 290,000 plan members, delivering insights into care delivery, cost containment, and regulatory compliance.
Key insights from the report:
- Healthcare costs continue to rise, with CBIZ data finding that cost per visit for inpatient, outpatient, and professional care increased from 2022 to 2024.
- CBIZ data shows that GLP-1s are a significant cost driver in employers’ pharmacy spend. GLP-1 spend as a percentage of overall pharmacy spend has increased from 9% in 2022 to 17% in 2024. This trend is expected to continue as these medications grow in popularity.
- Ongoing regulatory changes, specifically those occurring at the state level, are shifting employer-sponsored healthcare. Many of these regulations expand protections and accessibility for employees, and employers must continue to monitor relevant legislation to maintain compliance.
“Healthcare has never been more complex than it is right now,” said
The State of Healthcare Report provides a high-level overview of emerging risks and opportunities, featuring analysis from our experts on how to proactively tackle these challenges through data, innovation, and smarter benefits design.
To download the full report, visit 2025 State of Healthcare Report
About CBIZ
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520808811/en/
Media:
Source: